Enanta Pharmaceuticals has been granted a patent for compounds that inhibit coronavirus replication. The patent covers pharmaceutical compositions and methods for treating or preventing coronavirus infections. Formula (I) represents the compound structure. GlobalData’s report on Enanta Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Enanta Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Enanta Pharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. Enanta Pharmaceuticals's grant share as of February 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11919910B2) discloses a compound represented by Formula (I) and its various derivatives, along with pharmaceutically acceptable salts. The patent also covers pharmaceutical compositions containing the compound and a method for treating or preventing coronavirus infections in subjects by administering the compound or a combination of compounds.

The patent claims encompass a wide range of compounds and their derivatives, along with pharmaceutical compositions comprising these compounds for treating or preventing coronavirus infections. The method disclosed in the patent involves administering a therapeutically effective amount of the compound to subjects in need, with specific mention of various types of coronaviruses, including SARS-CoV-2. This patent highlights the potential use of the disclosed compounds in combating coronavirus infections, particularly relevant in the current global health scenario.

To know more about GlobalData’s detailed insights on Enanta Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies